|
|
 |
|
Viewing report
|
|
|
|
Monoclonal Antibodies Against Digestive System Cancers Patent Landscape 2010
France Innovation Scientifique et Transfert (FIST SA), Sep 2010, Pages: 111
In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a plateau since 2005.
The present report analyses the patent environment and highlights the various monoclonal antibodies that have been developed to diagnose and treat oesophageal, gastric, bile duct, gastro-intestinal, colorectal, hepatic, pancreatic and anal cancers. The major trend is the development of human immunoconjugates against colorectal cancers by targeting growth factor receptors. Although this sector is surrounded by Roche and its subsidiaries, other players, and especially big pharma and biotech companies, continue to develop antibodies targeting new antigens and/or having new properties.
In this competitive sector driven by an important market and where 3000 patent families have been filed, this study 'IP Overview – Monoclonal antibodies against digestive system cancers' provides you with a comprehensive panorama of the intellectual property landscape and helps you:
- Position your company’s R&D and IP Portfolio
- Identify key inventors and key players involved in the development of new monoclonal antibodies
- Understand the collaboration networks and their dynamics
- Discover new trends and emerging topics
Please note that a three months access to the full patent database is also included
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs
Future Oncology
The Future of the Biologicals Market: Market overview, innovations and company profiles
Opportunities for Monoclonal Antibodies: Where Companies Are Spending Their Antibody Dollars
The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Malaria Patent Landscape - 2009/08
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Industry Analysis - How Companies Can Maintain the Market Success of Cancer MAbs
|
|
|
|
